IMMUNOTECH-B Reports Half-Year Results with Narrowed Loss
Stock News
Aug 21
IMMUNOTECH-B (06978) has released its interim financial results for the six months ended June 30, 2026, revealing a significant improvement in its bottom line.
During the period, the group recorded other income of 12.597 million yuan, reflecting a modest year-on-year decline of 3.4%. However, the loss attributable to shareholders of the company narrowed considerably to 69.867 million yuan, representing a substantial 45.9% reduction compared to the same period last year.
The company reported a basic loss per share of 0.11 yuan for the six-month reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.